Outcomes and Safety in Advanced Ovarian Cancer Patients Based on Homologous Recombination Status Comparing Olaparib Plus Bevacizumab Versus Standard Treatments in a Real-World Study

What this Trial Is About

Researchers are evaluating clinical outcomes and safety in patients diagnosed with advanced high-grade ovarian cancer, focusing on how the tumors homologous recombination HR status affects treatment responses. This observational study involves two patient groups based on HR status, aiming to understand the impact of matched therapies in a real-world setting from January 2021 to January 2026. Patients are divided into two cohorts Cohort A includes those with homologous recombination deficient HRD ovarian cancer treated with Olaparib plus Bevacizumab as maintenance therapies after responding to first-line platinum-based chemotherapy Cohort B includes homologous recombination proficient HRP patients receiving standard clinical care chosen by their doctors. Participants are enrolled either retrospectively if already treated or prospectively if starting first-line therapy, based on tumor HR test results. During the study, researchers will monitor clinical outcomes and safety for up to three years after enrollment. Data collection includes treatment details, responses, and adverse events to evaluate therapy effects in each group. Participants provide informed consent and remain under regular care, with outcomes tracked to understand the real-world effectiveness and safety of targeted therapies for advanced ovarian cancer.

Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario